Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Steminent Biotherapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was NT$5,455.07 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Steminent Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-202.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Steminent Biotherapeutics EV-to-EBIT Related Terms
Steminent Biotherapeutics EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7729 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Steminent Biotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steminent Biotherapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Steminent Biotherapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Steminent Biotherapeutics's EV-to-EBIT falls into.
Steminent Biotherapeutics's current Enterprise Value is NT$5,334.02 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Steminent Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-202.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Steminent Biotherapeutics (ROCO:7729) has a EV-to-EBIT of -26.34 as of Sep. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Steminent Biotherapeutics and its competitors. According to the industry distribution chart, Steminent Biotherapeutics ranks #999999 out of 364 companies in the Biotechnology industry.
Is Steminent Biotherapeutics' EV-to-EBIT too high?
Steminent Biotherapeutics' current EV-to-EBIT is -26.34. Based on the distribution chart, Steminent Biotherapeutics ranks #999999 out of 364 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Steminent Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Steminent Biotherapeutics' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Steminent Biotherapeutics ranks #999999 out of 364 companies for EV-to-EBIT. This places Steminent Biotherapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.69, based on 364 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Steminent Biotherapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Steminent Biotherapeutics's current EV-to-EBIT is -26.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steminent Biotherapeutics stock overvalued right now?
Steminent Biotherapeutics (ROCO:7729) has a current EV-to-EBIT of -26.34. The current EV-to-EBIT is -26.34. Steminent Biotherapeutics' overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Steminent Biotherapeutics (ROCO:7729), the current EV-to-EBIT is -26.34 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.
19GF Score
Get the complete analysis for ROCO:7729
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7729 has been successfully added to your 
